Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7694213 | 0.89 | G6PD (0.47) | G6PDTLR9GAASTAT3CTSK | |
| SCHEMBL7697212 | 0.89 | G6PD (0.47) | G6PDTLR9GAASTAT3CTSK | |
| SCHEMBL7694210 | 0.89 | G6PD (0.47) | G6PDTLR9GAASTAT3CTSK | |
| SCHEMBL4573458 | 0.85 | G6PD (0.41) | G6PDTLR9GAASTAT3CTSK | |
| SCHEMBL4573464 | 0.85 | G6PD (0.41) | G6PDTLR9GAASTAT3CTSK | |
| SCHEMBL4858307 | 0.84 | G6PD (0.43) | G6PDTLR9GAASTAT3CTSK | |
| SCHEMBL6555452 | 0.84 | G6PD (0.43) | G6PDTLR9GAASTAT3CTSK | |
| SCHEMBL9719755 | 0.84 | G6PD (0.43) | G6PDTLR9GAASTAT3CTSK | |
| SCHEMBL28420820 | 0.83 | G6PD (0.42) | G6PDTLR9GAASTAT3CTSK | |
| SCHEMBL17735725 | 0.83 | KMT2A (0.43) | G6PDTLR9GAASTAT3CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171874-A1 | METHOD FOR THE REGIOSELECTIVE PREPARATION OF SUBSTITUTED BENZO[G]QUINOLINE-3-CARBONITRILES AND BENZO[G]QUINAZOLINES | WYETH (US) | 2008-07-17 | — | — | US | disclosed |
| US-7365197-B2 | Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1242382-B1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | BERGER DAN M | 2006-11-02 | — | — | US | disclosed |
| US-7105531-B2 | Tricyclic protein kinase inhibitors | WYETH (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060041127-A1 | Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines | WYETH | 2006-02-23 | — | — | US | disclosed |
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | WYETH | 2004-06-10 | — | — | US | disclosed |
| EP-1345889-A1 | METHOD FOR THE REGIOSELECTIVE PREPARATION OF SUBSTITUTED BENZO G]QUINOLINE-3-CARBONITRILES AND BENZO G]QUINAZOLINES | Wyeth (US) | 2003-09-24 | — | — | EP | disclosed |
| EP-1242382-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | Wyeth (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020091273-A1 | Method for the regioselective preparation of substituted benzo[g]quinoline3-carbonitriles and benzo[g]quinazolines | AMERICAN HOME PRODUCTS CORPORATION | 2002-07-11 | — | — | US | disclosed |
| WO-2002053528-A1 | METHOD FOR THE REGIOSELECTIVE PREPARATION OF SUBSTITUTED BENZO[G]QUINOLINE-3-CARBONITRILES AND BENZO[G]QUINAZOLINES | WYETH (US) | 2002-07-11 | — | — | WO | disclosed |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-13 | — | — | US | disclosed |
| WO-2001047892-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-07-05 | — | — | WO | disclosed |
| US-4536503-A | Naphthoxyalkylamines and related compounds as antiinflammatory agents | SYNTEX (U.S.A.) INC. (US) | 1985-08-20 | — | — | US | disclosed |
| EP-0082005-A2 | Naphthoxyalkylamines and related compounds, their preparation and antiinflammatory compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | CDK1, CDKN1A, CDK2 | G6PD 1343/4885TLR9 4848/4885GAA 2692/4885 |
| US-20080171874-A1 | METHOD FOR THE REGIOSELECTIVE PREPARATION OF SUBSTITUTED BENZO[G]QUINOLINE-3-CARBONITRILES AND BENZO[G]QUINAZOLINES | PDXK, PKD1, GLS | G6PD 1734/4885TLR9 4075/4885GAA 1134/4885 |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | CDK1, CDKN1A, CDK2 | G6PD 1475/4885TLR9 4853/4885GAA 2649/4885 |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | CDK1, CHEK1, ABL1 | G6PD 2005/4885TLR9 4589/4885GAA 2419/4885 |
| US-20060041127-A1 | Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines | PDXK, PKD1, GLS | G6PD 1734/4885TLR9 4075/4885GAA 1134/4885 |
| US-20020091273-A1 | Method for the regioselective preparation of substituted benzo[g]quinoline3-carbonitriles and benzo[g]quinazolines | PDXK, PKD1, PFKP | G6PD 2080/4885TLR9 3707/4885GAA 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.